Alto Neuroscience investors encouraged to contact Faruqi & Faruqi for legal options.

Faruqi & Faruqi LLP is investigating potential claims against Alto Neuroscience, Inc. (NYSE: ANRO) related to the company's initial public offering on February 2, 2024, and the subsequent Class Period. Investors who purchased Alto stock during this time may have suffered losses and are encouraged to contact James Wilson directly to discuss their options.

Faruqi & Faruqi LLP, a leading national securities law firm, has initiated an investigation into potential claims against Alto Neuroscience, Inc. (NYSE: ANRO). The firm is encouraging investors who purchased Alto stock during the company's initial public offering (IPO) on February 2, 2024, and the subsequent Class Period to contact them for further information.

The investigation centers on allegations that Alto and its executives made false and/or misleading statements or failed to disclose material adverse information. Specifically, the firm is looking into claims that:

1. ALTO-100 was less effective in treating Major Depressive Disorder (MDD) than investors were led to believe.
2. As a result, ALTO-100's clinical, regulatory, and commercial prospects were overstated.
3. Consequently, Alto's business and/or financial prospects were overstated.
4. The Company's public statements were materially false and misleading at all relevant times.

On October 22, 2024, Alto issued a press release announcing that ALTO-100 did not meet its primary endpoint in a Phase 2b trial evaluating it as a treatment for MDD. This announcement led to a significant drop in Alto's stock price, falling $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.

Investors who purchased or otherwise acquired Alto securities between February 2, 2024, and October 22, 2024, are encouraged to contact Faruqi & Faruqi partner James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The deadline to seek the role of lead plaintiff in a federal securities class action is September 19, 2025.

Faruqi & Faruqi LLP has a proven track record of recovering hundreds of millions of dollars for investors since its founding in 1995. The firm also encourages anyone with information regarding Alto's conduct to contact them.

For more information, visit [Faruqi & Faruqi LLP's website](https://www.faruqilaw.com/ANRO) or contact Josh Wilson directly.

References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143938/0/en/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Alto-Neuroscience.html
[2] https://www.marketscreener.com/news/investor-deadline-approaching-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-al-ce7d59d9d08fff27
[3] https://www.globenewswire.com/news-release/2025/09/02/3142989/0/en/INVESTOR-ALERT-Holzer-Holzer-LLC-Reminds-Investors-of-September-19-2025-Lead-Plaintiff-Deadline-in-the-Alto-Neuroscience-Inc-ANRO-Class-Action-Investors-With-Significant-Losses-Enc.html